Pulmonale Hypertonie bei COPD und Emphysem – klinische Implikationen

Pneumologie 2013; 67(S 02): S115-S116
DOI: 10.1055/s-0033-1344746

Extended Abstract

Pulmonary Hypertension in COPD and Emphysema – Clinical Implications

J. Behr

Medizinische Klinik und Poliklinik V, Klinikum der Ludwig-Maximilians-Universität, München

Literatur
1 Bishop JM. Cardiovascular complications of chronic bronchitis and emphysema. Med Clin North Am 1973; 57: 771-780
2 Chaouat A, Bugnet AS, Kadaoui N et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 189-194
3 Bianco I, Gimeno E, Munoz PA et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270-278
4 Lederer DJ, Bartels MN, Schluger NW et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9: 268-75
5 Bianco I, Santos S, Gea J et al. Sildenafil to improve respiratory rehabilitation in COPD: A controlled trial. Eur Respir J 21.02.2013; ERJ Express.
6 Hilde JM, Skjørten I, Hansteen V et al. Haemodynamic responses to exercise in patients with COPD. Eur Respir J 2013; 41: 1031-1041
7 Naije R, Boerrigter BG. Pulmonary hypertension at exercise in COPD: does it matter?. Eur Respir J 2013; 41: 1002-1004
8 Boerrigter BG, Bogaard HJ, Trip P et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142: 1166-1174